rs151242354

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PP3_ModeratePP5_Very_Strong

The NM_000124.4(ERCC6):​c.2167C>T​(p.Gln723Ter) variant causes a stop gained, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000249 in 1,613,370 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.000086 ( 0 hom., cov: 31)
Exomes 𝑓: 0.00027 ( 0 hom. )

Consequence

ERCC6
NM_000124.4 stop_gained, splice_region

Scores

5
1
1
Splicing: ADA: 0.9999
2

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:13

Conservation

PhyloP100: 10.0
Variant links:
Genes affected
ERCC6 (HGNC:3438): (ERCC excision repair 6, chromatin remodeling factor) This gene encodes a DNA-binding protein that is important in transcription-coupled excision repair. The encoded protein has ATP-stimulated ATPase activity, interacts with several transcription and excision repair proteins, and may promote complex formation at DNA repair sites. Mutations in this gene are associated with Cockayne syndrome type B and cerebrooculofacioskeletal syndrome 1. Alternative splicing occurs between a splice site from exon 5 of this gene to the 3' splice site upstream of the open reading frame (ORF) of the adjacent gene, piggyback-derived-3 (GeneID:267004), which activates the alternative polyadenylation site downstream of the piggyback-derived-3 ORF. The resulting transcripts encode a fusion protein that shares sequence with the product of each individual gene. [provided by RefSeq, Mar 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP3
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF. Scorers claiming Uncertain: max_spliceai. No scorers claiming Benign.
PP5
Variant 10-49482689-G-A is Pathogenic according to our data. Variant chr10-49482689-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 190160.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ERCC6NM_000124.4 linkuse as main transcriptc.2167C>T p.Gln723Ter stop_gained, splice_region_variant 10/21 ENST00000355832.10
ERCC6NM_001346440.2 linkuse as main transcriptc.2167C>T p.Gln723Ter stop_gained, splice_region_variant 10/21

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ERCC6ENST00000355832.10 linkuse as main transcriptc.2167C>T p.Gln723Ter stop_gained, splice_region_variant 10/211 NM_000124.4 P1Q03468-1

Frequencies

GnomAD3 genomes
AF:
0.0000856
AC:
13
AN:
151928
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.0000484
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000193
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000637
AC:
16
AN:
251352
Hom.:
0
AF XY:
0.0000662
AC XY:
9
AN XY:
135852
show subpopulations
Gnomad AFR exome
AF:
0.000185
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000114
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000266
AC:
389
AN:
1461442
Hom.:
0
Cov.:
31
AF XY:
0.000252
AC XY:
183
AN XY:
727018
show subpopulations
Gnomad4 AFR exome
AF:
0.0000598
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000345
Gnomad4 OTH exome
AF:
0.0000662
GnomAD4 genome
AF:
0.0000856
AC:
13
AN:
151928
Hom.:
0
Cov.:
31
AF XY:
0.0000944
AC XY:
7
AN XY:
74182
show subpopulations
Gnomad4 AFR
AF:
0.0000484
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.000193
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000147
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000176
Hom.:
0
Bravo
AF:
0.000113
TwinsUK
AF:
0.00108
AC:
4
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000465
AC:
4
ExAC
AF:
0.0000412
AC:
5
EpiCase
AF:
0.00
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Cockayne syndrome type 2 Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingClaritas GenomicsJan 07, 2013- -
Pathogenic, criteria provided, single submitterclinical testingMolecular Genetics, Royal Melbourne HospitalMar 30, 2023This sequence change is predicted to create a premature termination codon at position 723 in exon 10 (of 21) of ERCC6, p.(Gln723*). However, it has been demonstrated in RNA assays that this variant causes in-frame exon 10 skipping (p.Phe665_Gln723del) leading to the removal of the helical-like domain III, which the role of is not well-established (PMID: 29572252). The variant is present in a large population cohort at a frequency of 0.007%, which is consistent with a recessive condition (rs151242354, 20/282,734 alleles, 0 homozygotes in gnomAD v2.1). The variant has been identified as homozygous and compound heterozygous with a second pathogenic allele in multiple individuals with Cockayne syndrome spanning the full phenotype spectrum and mostly originating from the United Kingdom (PMID: 25326635, 29572252). Defective post-UV recovery of RNA synthesis has also been demonstrated in the cells of affected individuals (PMID: 29572252). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_VeryStrong, PVS1_Moderate, PM2, PP4. -
Likely pathogenic, no assertion criteria providedclinical testingGenomics England Pilot Project, Genomics England-- -
Pathogenic, criteria provided, single submitterclinical testingVictorian Clinical Genetics Services, Murdoch Childrens Research InstituteMay 21, 2020Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0108 - This gene is known to be associated with both recessive and dominant disease. However only recessive inheritance has been reported for Cockayne syndrome, type B (OMIM) (N) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (exon 10 of 21). (P) 0251 - Variant is heterozygous. (N) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (22 heterozygous, 0 homozygous). (P) 0701 - Comparable variants also predicted to result in NMD, have very strong previous evidence for pathogenicity for Cockayne syndrome (ClinVar, Decipher). (P) 0801 - Strong previous evidence of pathogenicity in multiple unrelated individuals with Cockayne syndrome (ClinVar, Decipher, Laugel, V. et al. (2010)) (P) 1206 - Variant is paternally inherited. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsSep 01, 2017This mutation has been previously reported as disease-causing and was found twice in our laboratory in trans with another pathogenic mutation in patients, including one with suspected diagnosis of Cockayne syndrome. Heterozygotes are expected to be asymptomatic carriers. -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingGeneDxAug 04, 2022Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21228398, 19894250, 23311583, 25326635, 27356891, 29572252, 31980526) -
Pathogenic, criteria provided, single submitterclinical testingInvitaeJan 18, 2024This sequence change creates a premature translational stop signal (p.Gln723*) in the ERCC6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ERCC6 are known to be pathogenic (PMID: 18628313, 29572252). This variant is present in population databases (rs151242354, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with Cockayne syndrome (PMID: 19894250). ClinVar contains an entry for this variant (Variation ID: 190160). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Likely pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityOct 20, 2022- -
Cerebrooculofacioskeletal syndrome 1;C0242379:Lung cancer;C0265201:DE SANCTIS-CACCHIONE SYNDROME;C0751038:Cockayne syndrome type 2;C3151063:Age related macular degeneration 5;C3551173:UV-sensitive syndrome 1;C4310783:Premature ovarian failure 11 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsSep 27, 2021- -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJul 17, 2023The c.2167C>T (p.Q723*) alteration, located in exon 10 (coding exon 9) of the ERCC6 gene, consists of a C to T substitution at nucleotide position 2167. This changes the amino acid from a glutamine (Q) to a stop codon at amino acid position 723. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on data from gnomAD, the T allele has an overall frequency of 0.007% (20/282734) total alleles studied. The highest observed frequency was 0.013% (17/129108) of European (non-Finnish) alleles. This variant has been reported to be homozygous or compound heterozygous in multiple individuals with features consistent with ERCC6-related disorders (Laugel, 2010; Calmels, 2018). Based on the available evidence, this alteration is classified as pathogenic. -
ERCC6-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingIllumina Laboratory Services, IlluminaDec 10, 2018The ERCC6 c.2167C>T (p.Gln723Ter) variant is a stop-gained in the splice region variant that is predicted to result in premature truncation of the protein. The p.Gln723Ter variant has been reported in two studies in which it is found in a total of 12 individuals affected with Cockayne syndrome-B, including in two in a homozygous state and in ten in a compound heterozygous state with a unique null variant (Laugel et al. 2010; Calmels et al. 2018). Control data are unavailable for this variant, which is reported at a frequency of 0.00047 in the European American population of the Exome Sequencing Project. The p.Gln723Ter variant has not been reported in the literature in association with macular degeneration or cerebrooculofacioskeletal syndrome. Based on the collective evidence and the potential impact of stop-gained variants, the p.Gln723Ter variant is classified as pathogenic for ERCC6-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Cockayne syndrome Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJun 20, 2022Variant summary: ERCC6 c.2167C>T (p.Gln723X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic (e.g. c.3862C>T (p.Arg1288X); c.2569C>T (p.Arg857X); ClinVar). The variant allele was found at a frequency of 6.4e-05 in 251352 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ERCC6 causing Cockayne Syndrome (6.4e-05 vs 0.0016). c.2167C>T has been reported in the literature in multiple homozygous and compound heterozygous individuals affected with Cockayne Syndrome and is seen primarily in individuals from the UK, suggesting a potential founder effect (e.g. Laugel_2010, Clamels_2018). These data indicate that the variant is very likely to be associated with disease. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Five laboratories classified the variant as pathogenic and one as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
DE SANCTIS-CACCHIONE SYNDROME Pathogenic:1
Likely pathogenic, no assertion criteria providedclinical testingCounsylJun 26, 2017- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
0.43
D
BayesDel_noAF
Pathogenic
0.66
CADD
Pathogenic
46
DANN
Uncertain
1.0
Eigen
Pathogenic
1.2
Eigen_PC
Pathogenic
1.1
FATHMM_MKL
Pathogenic
1.0
D
MutationTaster
Benign
1.0
A;A
Vest4
0.97
GERP RS
5.8
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
0.98
SpliceAI score (max)
0.27
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.27
Position offset: -2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs151242354; hg19: chr10-50690735; API